BC-M249: Bill M 249: Pharmaceutical Risk Management and Accountability Act

This bill primarily affects pharmaceutical wholesalers who distribute the designated drug categories in British Columbia — companies involved in supplying COVID-19 vaccines, safer supply opioids, hormone therapies, and antidepressants to pharmacies, clinics, and health facilities. These wholesalers would be required to negotiate and sign government-approved risk management agreements, establish and administer compensation funds for patients harmed by their products, and indemnify the provincial government for related health care system costs — which represents a significant new financial and administrative burden. Pharmacists, physicians, nurse practitioners, and other practitioners who prescribe or dispense these drugs would also be directly affected, as they would be legally prohibited from providing these medications unless their supplier has a qualifying agreement in place. Smaller or regional drug wholesalers may find the financial exposure from compensation fund requirements and open-ended government indemnification obligations particularly difficult to absorb, potentially disrupting supply chains for widely used medications.